Medintech
30 employees on LinkedIn Β· 6 known investors
MedinTech develops motorized flexible endoscopes built on AI and robotics, offering precise, lightweight operation and AI-based procedure assistance for physicians. Its technology detects and classifies abnormal areas in real time to improve the accuracy of endoscopic diagnosis and clinical decision-making.
Also known as (μ£Ό)λ©λμΈν ν¬ Β· Mediintech Β· MedInTech Inc. Β· λ©λμΈν ν¬
Founders & leadership
Investors Β· 6
Also in the syndicate Β· 5
Company profile
researched Aug 2026MedInTech Inc. (λ©λμΈν ν¬) is a South Korean medical device company developing motorized flexible endoscopes that combine robotics with artificial intelligence. The company positions motorized flexible endoscopy as a new paradigm in the field, citing a precise and stable operating environment, a lightweight design, and AI-assisted procedural functions intended to reduce operator burden and improve the accuracy and consistency of procedures. Its software also detects and classifies abnormal areas in real time to support endoscopic diagnosis and clinical decision-making.
The product portfolio spans gastroscopes (MGS-400, MGS-410), colonoscopes (MCS-400, MCS-410), bronchoscopes (MBS-440, MBS-460), ureteroscopes, arthroscopes and cystoscopes, plus the ME-400 endoscopic imaging system and the MD-GA-300 AI abnormality detection (CADe) software. A set of motorized, AI-assisted functions is marketed under the names EndoPilot (detects the entry site and assists steering of the distal tip toward it), EndoTrack (detects abnormal areas and steers the tip to center them on screen), EndoMeasure (detects abnormal areas and estimates their length) and EndoResect (during ESD procedures, visually suggests an optimal path and assists steering along it). The company also operates an endoscopy training center.
Press coverage describes the core hardware as an electric endoscope that is more intuitive and about 50% lighter than conventional endoscopes, built on medical robot technology, together with AI-based anomaly detection software aimed at reducing misdiagnosis. As of May 2024 the electric digestive endoscopy system had obtained Class 2 medical device approval and was slated for market launch that year, with clinical trials underway at Seoul National University Hospital.
Founding story
MedInTech was founded in 2020 by CEO Lee Chi-won (Chiwon L.) and Vice President Kim Myung-joon, who had been researching endoscopy-related technologies at the state-funded Korea Electrotechnology Research Institute.
Business model
Development and commercialization of endoscopy hardware (gastroscopes, colonoscopes, bronchoscopes, ureteroscopes, arthroscopes, cystoscopes), an endoscopic imaging system, and AI software for computer-aided detection and motorized procedural assistance, sold for clinical use.
Traction
Class 2 medical device approval obtained for its electric digestive endoscopy system, with market launch of that system and its anomaly detection software planned for 2024; clinical trials underway with Seoul National University Hospital. Cumulative funding of more than 28 billion won (about $20.5 million) as of May 2024. Employee counts reported in the range of 11-50 (one source lists 30).
Latest developments
In May 2024 MedInTech announced a 20 billion won (approx. $14.6 million) Series B from nine venture capital firms, including existing backers Atinum Investment, FuturePlay, Smilegate Investment and Nextrans and new investors Industrial Bank of Korea, SL Investment, Hana Ventures, Wooshin Venture Investment and SCL Investment, to fund mass production and overseas expansion. The company's site lists an expanded product line across gastroscopes, colonoscopes, bronchoscopes, ureteroscopes, arthroscopes and cystoscopes, the ME-400 imaging system, CADe software and an endoscopy training center.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
Described in press coverage as a South Korean smart/electric endoscopy startup developing what is characterized as the world's first motorized endoscope, and listed as a MedTech Innovator portfolio company.
Technology
Motorization of flexible endoscopes combined with lightweight design and AI. Motorized control enables AI-based automatic steering of the distal tip: EndoPilot for entry-site detection and steering, EndoTrack for centering detected abnormalities on screen, EndoMeasure for lesion length estimation, and EndoResect for suggesting and following an optimal path during ESD. Separate CADe software (MD-GA-300) performs real-time detection and classification of abnormal areas. Reported hardware benefits include roughly 50% weight reduction versus conventional endoscopes and automated control, with AI additionally described as reconstructing blind spots.
Go-to-market
Physicians and hospitals performing endoscopic diagnosis and treatment, including gastrointestinal, bronchial and urological procedures; clinical collaboration includes Seoul National University Hospital.
Geography
Headquarters in Jongno-gu, Seoul (60 Daehak-ro and 223 Yulgok-ro), a manufacturing facility, and a Yangsan branch at 20 Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do. Overseas expansion was cited as a use of Series B proceeds.
History
Founded in 2020, the company raised a seed round the same year, followed by an 8 billion won (about $5.8 million) Series A in 2022 and a 20 billion won (about $14.6 million) Series B announced in May 2024, bringing cumulative investment past 28 billion won (about $20.5 million). By that point it had secured Class 2 medical device approval for its electric digestive endoscopy system and was running clinical trials with Seoul National University Hospital, with Series B proceeds earmarked for establishing mass production and overseas expansion.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 3
launches, deals, and filingsAnnounced a Series B of 20 billion won (about $14.6 million) from nine venture capital firms, including existing investors Atinum Investment, FuturePlay, Smilegate Investment and Nextrans and new investors Industrial Bank of Korea, SL Investment, Hana Ventures, Wooshin Venture Investment and SCL Investment. Proceeds are for establishing a mass production system and overseas expansion.
$14.6M source β
Clinical trials of the company's endoscopy technology were reported as underway with Seoul National University Hospital.
The company's electric digestive endoscopy system obtained Class 2 medical device approval, with a planned market launch alongside its AI anomaly detection software.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- Medintechmedintech.co.kr Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medintech do?
- Korean medical device company building motorized flexible endoscopes with AI-assisted steering and lesion detection.
- Who founded Medintech?
- Medintech was founded by Myungjoon Kim λ.
- Who are Medintech's investors?
- Medintech's investors include Atinum Investment Co. Ltd..